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A model for facilitating translational research and development in China 171arrangement, the Chinese University of Hong Kong (CUHK; Shatin, Hong Kong) and the Chinese
National Engineering Research Centre for Biomaterials (i.e., Main Centre) in Chengdu, People’s
Republic of China have decided to apply to establish the Hong Kong Branch of the CNERC for
Biomaterials at the CUHK. The effort in establishing the Hong Kong Branch of Biomaterials
seeks to promote further collaboration with the Main Centre with the goals of promoting syn-
ergy and a win-win cooperation between mainland China and Hong Kong in scientific research,
talent cultivation, clinically driven novel biomaterials product design, and preclinical and clin-
ical testing. It will thus become a model for the successful collaboration between the Hong
Kong research institutions and the mainland CNERCs in the area of biomaterials. Such initia-
tives will facilitate close collaboration in translational medicine associated with biomaterial
development and application.
Copyrightª 2014, The Authors. Published by Elsevier (Singapore) Pte Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Background on the establishment of the Hong
Kong Branch of the Chinese National
Engineering Research Centres
Chinese National Engineering Research Centres
The Chinese National Engineering Research Centres
(CNERCs) are under the auspices of the State Ministry of
Science and Technology (MOST; Beijing, China) and serve as
a major initiative in driving basic and applied technological
research and development (R&D) in mainland China; there
are more than 200 CNERCs in all major engineering areas in
mainland China [1]. The CNERCs focus on providing engi-
neering research and consultancy support to industries in-
cludes enhancing core competency on the transformation
of technology achievements for productivity; promoting a
higher level of maturity, compatibility, and engineering
standards in technology results; and providing technolog-
ical innovation support for national socioeconomic devel-
opment [1].
Hong Kong Branch of the CNERCs
In the autumn of 2011, vice-Premier Keqiang Li visited Hong
Kong and announced the establishment of a Hong Kong
Branch of the CNERCs [2]. The aim was to make the Hong
Kong Branch a major element in the National Engineering
Research Centre mechanism in which the Hong Kong Branch
would fully utilise Hong Kong’s advantages in technological
resources and realise a synergy of the respective strengths
of Hong Kong and the mainland. This would enhance the
capability in engineering and commercialisation, promote
the technological advancement of mainland industries and
the upgrading of Hong Kong’s industries, and enhance
overall competitiveness [2]. The essential requirement for
establishing the Hong Kong Branch is that there are already
approved CNERCs on the mainland. To start with, Hong
Kong Science Park was formally designated by the MOST of
the People’s Republic of China as a National High-tech
Industrialization (Partner) Base for Green Technology,
whereas the Hong Kong Applied Science and Technology
Research Institute (ASTRI; Shatin, Hong Kong) receivedapproval from the MOST in June 2013 to establish the Hong
Kong Branch of the National Engineering Research Centre
for Application-specific Integrated Circuit System in
collaboration with the Southeast University in Nanjing
(Nanjing, China) [3,4].Formation of the Working Group to apply for
the establishment of the Hong Kong Branch of
CNERCs for Biomaterials
Medical and socioeconomic demands
With significant improvements in living standards in China
and the aging population that accompanies these im-
provements, the number of patients with significant
musculoskeletal disorders such as osteoporosis and osteo-
arthritis has been increasing rapidly. The resulting clinical
or market demand for high-quality orthopaedic bio-
materials for clinical applications is very substantial. Ac-
cording to official statistics, 100 million patients have
osteoarthritis; as many as 300e400 million patients have
tooth defects and tooth loss; 70 million patients have
osteoporosis; nearly 10 million patients each year have
bone defects caused by illness, accidents, and sports in-
juries; and tens of millions of people require craniofacial
and breast cosmetic plastic surgeries [5,6]. The treatment
of these diseases requires biomaterials, thus creating a
huge market for the biomaterial industry. According to the
statistics, the market value of the biotechnology industry,
which includes biomaterials, had already exceeded 800
billion yuan in 2008 [7].
Biomaterials also have a very promising prospect in other
clinical applications such as in the diagnosis and treatment
of cardiovascular diseases, cancer, and other major dis-
eases. Biomaterials are primarily used as medical devices in
clinical applications in China and their products account for
approximately 40e50% of the medical devices market [7].
Research and development, testing, and clinical translation
of biomaterials as a high-value-added, technology-inten-
sive, low energy consumption, pollution-free high-tech in-
dustry are very consistent with the direction of the future
economy in mainland China and in Hong Kong. The
172 L. Bian et al.establishment of the biomaterials industry will effectively
promote the health of residents in mainland China and in
Hong Kong, and greatly promote local economic develop-
ment and the creation of high-tech jobs [2e4,8].
As early as the early 1980s, Professor Xingdong Zhang of
the Sichuan University (Sichuan, China), who is also
academician of the Chinese Academy of Engineering (Bei-
jing, China) and fellow of the United States National
Academy of Engineering (Washington, DC, USA), took the
lead in China to develop nearly 20 series and 200 types of
biomaterial implants for bone, teeth, soft tissue repair, and
artificial hip joints. Professor Zhang and his group promoted
the application of these biomaterial products in more than
600 hospitals. They also received good outcomes and six
registration certificates from the State Food and Drug
Administration. In 2000, the National Engineering Research
Centre for Biomaterials was officially established and
became the first open national biomaterials professional
R&D institute with a focus on the development of func-
tional biomaterial products and clinical translation [1,9].Figure 1 Paradigm for the clinically driven development of
biomaterials. CFDA Z China Food and Drug Administration.Formation of the Application Working Group
As early as 1996, Professor Zhang’s group began collabo-
rating with the Department of Orthopaedics and Trauma-
tology of the Chinese University of Hong Kong (CUHK;
Shatin, Hong Kong) and the Department of Mechanical En-
gineering of the Hong Kong University of Sciences and
Technology (HKUST; Clear Water Bay, Hong Kong) on
developing translation research on hydroxyapatiteetrical-
cium phosphate-based scaffold implantable biomaterials
for orthopaedic applications [10e12]. In May 2014, under
the backdrop of this development, biomaterial researchers
at the CUHKdwho were led by Professor Ling Qin of the
Faculty of Medicine, Professor Arthur Mak of the Faculty of
Engineering, and Professor Chi Wu of the Faculty of Scien-
cesdproposed to establish a multidisciplinary Hong Kong
Branch of the National Engineering Research Centre for
Biomaterials (hereafter referred to as the Hong Kong
Branch for Biomaterials). As mentioned previously, the
National Engineering Research Centre for Biomaterials
(i.e., the Main Centre listed in the CNERCs) is the only
National Engineering Research Centre that focuses on the
R&D and translation of biomaterials for clinical applica-
tions. Professor Xingdong Zhang (the academic leader of
the Centre) and Professor Zhongwei Gu (the Director of the
Centre and the principal scientist of Program 973) are
world-renowned experts in biomaterials. In China, Profes-
sor Zhang has been a pioneer in the research of bioactive
ceramics and coatings. His group has developed a series of
biomedical products for orthopaedic, dental, and other
relevant medical applications. Their research demon-
strated that inanimate calcium phosphate ceramics could
induce bone formation, and established the prototype of
biomaterial-induced bone induction theory. Professor
Zhang is also a pioneer in expanding new ways for devel-
oping a new generation of biomaterials. Professor Gu has
enjoyed worldwide recognition in the fields of polymer-
based biomaterials research, controlled-release systems
for drugs/bioactive substances, and nanobiomaterials.
Since the Centre’s establishment in China, it has had anindispensable role in the development and translation of
biomaterials, and has led the technical development and
clinical translation of orthopaedic biomaterials [8].
Through an amicable arrangement, the CUHK and the
CNERC for Biomaterials have decided to establish the Hong
Kong Branch of the CNERC for Biomaterials at CUHK. This
effort in establishing the Hong Kong Branch of Biomaterials
seeks to promote further collaboration with the Main Centre
with the goals of promoting synergy andwin-win cooperation
between mainland China and Hong Kong in scientific
research, talent cultivation, clinically driven novel bio-
materials product design, and preclinical and clinical
testing. It will thus become a model for the successful
collaboration between the Hong Kong research institutions
and themainland CNERCs in the area of biomaterials (Fig. 1).
The application for the Hong Kong Branch of CNERC for Bio-
materials is built on the foundation of synergistic strengths
and long-term collaboration. These are essential elements in
translational medicine, especially in the R&D of orthopaedic
materials, implants, and devices [12e19].
Missions of the Hong Kong Branch of
Biomaterials
Through a joint synergistic collaboration with the Main
Centre, the Hong Kong Branch of Biomaterials will under-
take the following missions to advance the engineering and
enterprising of biomaterials in China, especially in Hong
Kong. (1) To innovate biomaterials through their basic sci-
ence and their engineering technology, as driven by clinical
demands. (2) To develop new methods and models to
explore the molecular markers for biocompatibility
research and assessment of biomaterials. (3) To conduct
preclinical and clinical testing of biomaterials and conduct
the associated technology research for clinical applica-
tions. (4) To establish jointly with relevant enterprises a
demonstrative base for enterprising biomaterials and for
the clinical translation of their products. (5) To nurture
jointly with relevant disciplines at the CUHK and Sichuan
University, advanced professionals with integrative
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postgraduate continuing education for professionals in the
relevant industries. (6) To serve as a major window for
national and global collaborations in related sciences and
businesses for the purpose of academic exchanges, infor-
mation mining, and consultative services.
Work of the Hong Kong Branch of Biomaterials
Based on strength (e.g., manpower, infrastructure, track
records), the Hong Kong Branch of Biomaterials will
contribute in the following areas. (1) To propose the re-
quirements on the design and standards of biomaterials and
promote the clinical applications of mature products, based
on clinical needs. (2) To establish the theoretical and
experimental preclinical models and conduct clinical
testing and evaluations. (3) To conduct basic research on
the bioactivity and efficacy of biomaterials. (4) To develop
novel bioactive and functional biomaterials. (5) To assist
the development and improvement of preparing and pro-
cessing technology of advanced biomaterials (which in-
cludes three-dimensional printing). (6) To explore the
applications of biomaterials in stem cells, regenerative
medicine, and rehabilitation medicine.
Scope of collaboration with the Main Centre
The Hong Kong Branch of Biomaterials will effectively
cooperate with the Main Centre in mainland China on the
R&D of clinical needs-oriented advanced biomaterials,
basic research on materials and biology, animal testing, and
clinical testing. The specific cooperative measures include
R&D, training, and clinical service (Fig. 1) are as follows. (1)
To consolidate and develop in the areas of clinical appli-
cations (to further improve and establish indications for the
clinical use of biomaterials). (2) To collaborate on programs
(i.e. jointly complete the existing programs and jointly
apply for new programs). (3) To share information and in-
tellectual property (e.g., data obtained from animalFigure 2 The management structure and functions of the Hong Kmodels and clinical testing on biomaterials, new technol-
ogy, and new processes for preparation of biomaterials, and
information of Phase III and Phase IV clinical trials). (4) To
share resources (e.g., laboratory equipment, facilities, and
medical samples). (5) To exchange talent and training (e.g.,
jointly educate postgraduates towards joint postgraduate
program in biomaterials for medical applications, exchange
and train R&D and management personnel). The Ortho-
paedic Learning Centre in CUHK of the applicant unit has a
15-year history in training orthopaedic surgeons and
research scientists in AsianePacific region [20], which will
provide training and education to exchange personnel from
the Main Centre. (6) To collaborate with existing enter-
prises and incubate new businesses, promote effective
cooperation and the development of medical platforms
with industrial-academic research partnership. (7) To
conduct clinical studies and evaluations. (8) To provide
training and service for the marketed products.
The potential contributions of the Hong Kong Branch of
Biomaterials to R&D and the translation of biomaterials are
summarized, as follows. (1) To improve and establish in-
dications of new biomaterials in clinical uses. (2) To obtain
data on the efficacy of biomaterials in tests with animal
models and clinical applications and to optimize the prod-
ucts. The evaluation of biomaterials in the animal models
and clinical applications is an essential step during clinical
translation. The Hong Kong Branch of Biomaterials has
substantial scientific experience, experimental equipment,
and clinical resources in animal models and clinical testing
of biomaterials [21e23]. The Hong Kong Branch of Bio-
materials will provide important experimental data for
existing and innovative biomaterials via testing in animal
models and clinical testing, and thus will have a strong role
in further optimal design and clinical translation of bio-
materials. (3) To clarify the molecular mechanism of cell
and tissue responses to biomaterials. Biomaterials are in
close contact with human tissues and cells. The effects of
biomaterials on tissues and cells at molecular level deter-
mine their normal functions in the human body. The Hong
Kong Branch has a number of world-class scholars andong Branch of Biomaterials. R&DZ research and development.
Figure 3 The exchange mechanism between the Main Centre in the list of CNERCs in mainland China and the Hong Kong Branch of
Biomaterials. CNERCsZ Chinese National Engineering Research Centres; Dept.Z department; R&DZ research and development.
1 The Working Group members in the list in the proposal for the
Hong Kong Branch of CNERC of Biomaterials are the following: The
Faculty of Medicine of the Chinese University of Hong Kong
(Shatin, Hong Kong): Professors Ling Qin (Director of the Hong
174 L. Bian et al.experts in research studies related to molecular biology and
cellular biology. The Hong Kong Branch of Biomaterials will
make important contributions in revealing the molecular
mechanism of actions of biomaterials on cells and tissues,
and thereby effectively promote the optimal design of
biomaterials and improve the effectiveness of biomaterials
[24e26]. (4) To develop novel active and targeted bio-
materials. The Hong Kong Branch has strong research
strengths in materials science, particularly in the fields of
design and preclinical and clinical validation of metallic
materials and polymer materials for medical applications
[24e32]. The Hong Kong Branch of Biomaterials will make
important contributions to the development of innovative
metallic biomaterials, polymer implant biomaterials, drug
controlled-release materials and targeted delivery systems,
and modification of bioactive molecules on biomaterials.
(5) To develop advanced preparation and processing tech-
nology for biomaterials. The Hong Kong Branch of Bio-
materials has long-term research experience, high-end
research personnel, and complete research equipment in
the preparation and processing technology for emerging
biomaterials. The Hong Kong Branch will perform effective
work in fields such as three-dimensional printing and sur-
face coating technology biomaterials. (6) To study the ap-
plications of biomaterials in stem cells, regenerative
medicine, and rehabilitation medicine, the Hong Kong
Branch of Biomaterials will also focus on the development
of novel biomaterials, stem cell carriers, transcutaneous
implant materials, advanced exoskeleton materials, and
other key technologies that have an important role in
promoting the clinical applications of stem cells and novel
rehabilitation biomaterials.Kong Branch), Chun-Yiu Cheng, Kai Ming Chan, Gang Li, Kwok-Sui
Leung, Shekhar-Madhukar Kumta, and Wing-Hoi Cheung. Faculty
of Engineering of the Chinese University of Hong Kong (Shatin,
Hong Kong): Professors Arthur Mak (codirector of the Hong Kong
Branch), Charlie Wang, Jonathan Choi, Li Zhang, Wei Hsin Liao,
Liming Bian, and Douglas Yung. Faculty of Science of the Chinese
University of Hong Kong: Professors Chi Wu [codirector of the
Hong Kong Branch and academician of the Chinese Academy of
Science (Beijing, China)], Michael Chan, and To Ngai.Management system and operation mechanism
proposed for the Hong Kong Branch of
Biomaterials
Based on synergistic collaboration between medical
expertise and engineering expertise, the administrationunit of the Hong Kong Branch of Biomaterials will be
established at the Faculty of Medicine of the CUHK (Shatin,
Hong Kong). Professor Ling Qin, who is director of the
Musculoskeletal Research Laboratory in the Department of
Orthopaedics and Traumatology of the CUHK, will assume
the post as the director of the Hong Kong Branch. Professor
Fuk-Tat Mak (director of the Biomedical Engineering Divi-
sion of the CUHK) and Professor Chi Wu (who is a Wei Lun
Professor of Chemistry at the Department of Chemistry of
the CUHK) will serve as the codirectors of the Hong Kong
Branch of Biomaterials. To achieve effective management
and implementation of the overall project and tasks, the
Hong Kong Branch will organize and coordinate the faculty
members who are engaged in teaching and researching
biomaterials from the Faculty of Medicine, the Faculty of
Engineering, and the Faculty of Science at the CUHK to
consolidate the existing interdisciplinary cooperation and
further promote collaborative research with the Main
Centre. Professor Qin, Professor Mak, and Professor Wu and
the Working Group1 have proposed establishing a multi-
centre biomaterial research institute by integrating
research strengths from the Faculty of Medicine, the Fac-
ulty of Engineering, and the Faculty of Science at the CUHK
[24e26]. Professor Francis Chan, who is dean of the Faculty
of Medicine at the CUHK, will be chairman of the
Figure 4 The diagram shows the complementation and cooperation between the Main Centre and the Hong Kong Branch of
Biomaterials. R&D Z research and development.
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the post as vice-chairmen are Professor Wong Ching Ping,
who is Dean of the Faculty of Engineering and academician
of the Chinese Academy of Engineering (Beijing, China) and
the United States National Academy of Engineering, and
Professor Henry Nai-Ching Wong, who is Dean of the Faculty
of Science and academician of Chinese Academy of Sci-
ences (Beijing, China). An advisory committee and an ex-
ecutive core group, which includes the responsible persons
of the Main Centre, will be established. The management
structures and the functions of the Main Centre of CNERC in
mainland China and the Hong Kong Branch have been pro-
posed (Fig. 2). The exchange mechanism between the Main
Centre and its Hong Kong Branch is also listed for the syn-
ergistic running of bilateral collaboration (Fig. 3).
Synergy should be built on a strong foundation of
biomaterial research at the Main Centre and the Hong Kong
Branch by the appropriate alignment of research directions
(Fig. 4). The establishment of the Hong Kong Branch of
Biomaterials will lead to the development of biomaterial
industries in the region, which is consistent with the na-
tional strategic investment in new materials and biomedical
technology.
In summary, biomaterials and key technologies have
made great progress in recent years in China. However, a
large gap remains between the technical level of bioma-
terial products in China and internationally. Therefore,
further development of the biomaterial industry in China is
in urgent need of promoting cooperation between differentscientific institutes with complementary strengths. The
National Engineering Research Centre for Biomaterials and
the Hong Kong Branch of Biomaterials in CUHK jointly
established by the Faculty of Medicine, Faculty of Engi-
neering, and Faculty of Science of the CUHK will favourably
complement each other. The establishment of the Hong
Kong Branch of Biomaterials will further enhance the R&D
level of biomaterials in China and promote translation and
clinical applications of high-end biomaterials.
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